Viral Infections (without HIV) | Leukemia & Proliferative Disorders of Hematic Cells | Lymphomas & Myelomas
Patients with hematologic malignancies may be at higher risk of hepatitis B reactivation in spite of lamivudine prophylaxis
Byung-Su Kim*, Won Kim, Inho Kim, Soo-Mee Bang, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim
*Corresponding author: Byung-Su Kim
Department of Internal Medicine, Seoul Metropolitan Boramae Hospital, Seoul, Korea, South
F1000Posters 2010, 1: 181 (poster) [ENGLISH]
Poster [1.10 MB]
Presented at
51st American Society of Hematology Annual Meeting 2009,
5 - 8 Dec 2009, 1389
Although lamivudine (LMV) prophylaxis is recommended for chronic hepatitis B (HBV) patients undergoing cytotoxic chemotherapy for their malignant disease, viral reactivation sometimes occurs during or after LMV administration. The aims of this study are to determine predictors of LMV prophylaxis failure and to evaluate the relative risk of failure in patients with hematologic malignancies.
Main conclusion: We conclude that patients with hematologic malignancies or high serum HBV DNA titer are at greater risk of prophylaxis failure and need more intensive antiviral prophylaxis.
No relevant conflicts of interest declared.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
